EUVIMEDEUVIMED entdecken
Open Access

Naringin prevents heart mitochondria dysfunction during diabetic cardiomyopathy in rats

Ilya B Zavodnik, Tatsiana A Kavalenia, Siarhei N Kirko, Elena B Belonovskaya, Irina A Kuzmitskaya, Yulia V Eroshenko, Elena A Lapshina, Vyacheslav U Buko

ADMET and DMPK · 25.01.2025 · 2571

DOI: 10.5599/admet.2571 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ADMET and DMPK, online erschienen am 25.01.2025. Verfasst von Ilya B Zavodnik und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, Yanka Kupala State University of Grodno, Bulvar Leninskogo Komsomola, 5, 230009 Grodno, Grodno, Belarus. Die Arbeit wurde bisher 5-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and purpose: Cardiac mitochondria dysfunction plays a central pathophysiological role in the abnormal glucose metabolism in the heart and in diabetic cardiomyopathy. The present study evaluated the effects of flavonoid glycoside naringin treatment on the interconnection between changes in cardiac mitochondria oxygen consumption, membrane potential and mitochondrial Ca2+ sensitivity during type 1 diabetes. Experimental approach: Type 1 diabetes was induced by an intraperitoneal injection of streptozotocin (40 mg/kg) in rats and islet morphology, glucose and insulin levels, changes in heart mitochondria respiration, membrane potential, spontaneous and Ca2+ - induced mitochondrial permeability transition (MPT) pore opening were evaluated. Key results: Diabetes resulted in typical signs of hyperglycemia, which were accompanied by a rat cardiac mitochondria dysfunction, manifested by decreased V2 and V3 rates of oxygen consumption, while the initial membrane potential value remained unchanged. The rates of Ca2+-induced MPT pore opening and Ca2+-induced membrane potential dissipation in isolated mitochondria decreased under type 1 diabetes. The naringin treatment (40 mg/kg of the body weight, 4 weeks) partially recovered impaired cardiac mitochondria respiration, decreased spontaneous and increased Ca2+-induced MPT pore opening, improved pancreatic islets morphology and dystrophic changes, lowered glycated hemoglobin and blood plasma urea, and decreased the oxidative stress level with glucose or insulin concentrations remaining unchanged in diabetic animals. Conclusions: Naringin administration demonstrated beneficial effects during type 1 diabetes and represents a promising therapeutic (or nutriceutical) approach for diabetes treatment.

Schlagwörter

Stichwörter der Autor:innen

Cardiac mitochondriaflavonoidsisletsrespiration

Autor:innen und Institutionen

  • Department of Biochemistry, Yanka Kupala State University of Grodno, Bulvar Leninskogo Komsomola, 5, 230009 Grodno, Grodno, Belarus.
  • Division of Biochemical Pharmacology, Institute of Biochemistry of Biologically Active Compounds, National Academy of Sciences, Bulvar Leninskogo Komsomola, 50, 230030 Grodno, Belarus.

Zitieren

APA

Zavodnik, I. B., Kavalenia, T. A., Kirko, S. N., Belonovskaya, E. B., Kuzmitskaya, I. A., Eroshenko, Y. V., Lapshina, E. A., & Buko, V. U. (2025). Naringin prevents heart mitochondria dysfunction during diabetic cardiomyopathy in rats. ADMET and DMPK, 2571. https://doi.org/10.5599/admet.2571

Vancouver

Zavodnik IB, Kavalenia TA, Kirko SN, Belonovskaya EB, Kuzmitskaya IA, Eroshenko YV, et al. Naringin prevents heart mitochondria dysfunction during diabetic cardiomyopathy in rats. ADMET and DMPK. 2025:2571. doi:10.5599/admet.2571

BibTeX
@article{Zavodnik2025,
  author = {Zavodnik, Ilya B and Kavalenia, Tatsiana A and Kirko, Siarhei N and Belonovskaya, Elena B and Kuzmitskaya, Irina A and Eroshenko, Yulia V and Lapshina, Elena A and Buko, Vyacheslav U},
  title = {Naringin prevents heart mitochondria dysfunction during diabetic cardiomyopathy in rats},
  journal = {ADMET and DMPK},
  year = {2025},
  pages = {2571},
  doi = {10.5599/admet.2571}
}
Kostenlos starten →